Will Big Pharma get the bug for microbiome therapies?
The exciting field of microbiome therapeutics offers many opportunities for ‘Big Pharma’ players that are staring over the exclusivity cliff, say Craig Thomson, Leena Contarino and Andrew Wells of HGF.
Why things could get ugly over COVID-19 patents
Foreign patents protecting COVID-19 treatments may stall efforts to protect citizens, says Mark Engelman of Hardwicke chambers.
COVID-19: governments look to shield companies from IP enforcement
The UK government’s indemnifying of ventilator manufacturers is a smart solution to potential licensing obstacles, says Andrew Pitts of Mewburn Ellis.
Patent pools: should rights owners give up their IP?
Pressure is building on IP owners to offer up access to technology that could help fight COVID-19. Rory O'Neill looks at some of the implications for the patent system.
Compulsory licensing in Canada—revisited
New legislation has been enacted to help in the efforts to deal with the COVID-19 outbreak, as Daphne Lainson and Nancy Pei of Smart & Biggar report.
COVID-19: patent procurement and licensing
Jonathan Tietz, Jason Mock, and Kristel Schorr of Foley & Lardner offer their thoughts on patent procurement and licensing for COVID-19-related technologies.
UK patent system ‘no obstacle’ for ventilator production
Richard Fawcett, senior associate at Powell Gilbert, outlines why the UK patent system poses no obstacle to the UK government’s rallying call for ventilator production amid the COVID-19 pandemic.
Broad Institute down (but not out) in the European fight over CRISPR IP
The search for clarity goes on as Broad gears up for another set of legal challenges, as Claire Irvine, partner at HGF, explains.
Global IP Exchange Europe: IP leaders’ investment priorities revealed
Ahead of the Global IP Exchange Europe on March 9-11 in Berlin, the event’s organisers surveyed senior executives to find out their IP, patent, trademark, and brand protection investment priorities for the next 6-12 months.
Conference preview: 12th Pharma & Biotech Patent Litigation
Secondary medical use case trends and research exemptions are just two issues set to be discussed at C5’s 12th Pharma & Biotech Patent Litigation meeting, on February 25–26 in Amsterdam.
